Inactive Instrument

NVN Liquidation, Inc.

NOVN

US66988N2053

Novan Seeks FDA Approval of Molluscum Contagiosum Treatment

January 06, 2023 at 08:33 am

By Colin Kellaher

Novan Inc. on Friday said it has filed with the U.S. Food and Drug Administration seeking marketing approval of its berdazimer gel 10.3% product for the topical treatment of the skin disease molluscum contagiosum.

The Durham, N.C., medical-dermatology company said it anticipates a potential FDA green light in the first quarter of 2024, assuming the agency accepts the filing under its typical 12-month review process.

Novan said berdazimer gel has the potential to be the first FDA-approved prescription product for the treatment of molluscum contagiosum, a common viral skin infection that causes round, firm bumps.

Shares of Novan, which closed Thursday at $2.04, were recently up 3.4% in premarket trading Friday.

Write to Colin Kellaher at colin.kellaher@wsj.com

(END) Dow Jones Newswires

01-06-23 0833ET

Latest news about NVN Liquidation, Inc.

NVN Liquidation, Inc. Announces Board Resignations	05-01	CI
First Amended Combined Liquidation Plan and Disclosure Statement Filed by NVN Liquidation, Inc.	01-16	CI
Modified Disclosure Statement Approved on Interim Basis for NVN Liquidation, Inc.	12-19	CI
First Motion for Exclusivity Period Extension Approved For NVN Liquidation, Inc.	11-30	CI
Combined Liquidation Plan and Disclosure Statement Filed by NVN Liquidation, Inc.	11-22	CI
First Motion for Exclusivity Period Extension Filed by NVN Liquidation, Inc.	11-12	CI
Novan, Inc. has Changed its Name to NVN Liquidation, Inc	23-10-20	CI
Novan, Inc. Announces the Resignation of John M. Gay as Chief Financial Officer	23-09-27	CI
Novan, Inc. Announces the Resignation of John M. Gay as Secretary	23-09-27	CI
Ligand Pharmaceuticals Incorporated completed the acquisition of Substantially All of the Assets of Novan, Inc. for $12.2 million.	23-09-26	CI
Motion for Asset Sale Approved for Novan, Inc.	23-09-12	CI
Motion for Asset Sale Approved for Novan, Inc.	23-09-12	CI
Notice of selection of Successful Bidder Filed by Novan, Inc.	23-09-01	CI
Notice of selection of Successful Bidder Filed by Novan, Inc.	23-08-31	CI
Final DIP Financing Approved for Novan, Inc.	23-08-21	CI
Bidding Procedure Approved for Novan, Inc.	23-08-15	CI
Novan, Inc.(OTCPK:NOVN.Q) dropped from NASDAQ Composite Index	23-07-25	CI
Interim DIP Financing Approved for Novan, Inc.	23-07-21	CI
Novan, Inc.(NasdaqCM:NOVN) dropped from S&P TMI Index	23-07-20	CI
Motion for Joint Administration Approved for Novan, Inc.	23-07-19	CI
Sector Update: Health Care Stocks Slipping Late Monday	23-07-17	MT
Top Midday Decliners	23-07-17	MT
Sector Update: Healthcare Stocks Easing Monday Afternoon	23-07-17	MT
Novan Files for Chapter 11 Bankruptcy Protection, to Sell Nearly All Assets to Ligand Pharmaceuticals	23-07-17	MT
Novan Files Voluntary Chapter 11 Petition	23-07-17	MT

Chart NVN Liquidation, Inc.

Duration

Period

More charts

Company Profile

NVN Liquidation, Inc., formerly Novan, Inc., has filed a voluntary petition under Chapter 11 of the U.S. Bankruptcy Code and is winding down its business. The Company has no business operations.

Sector

Investment Holding Companies

More about the company

Sector Shell Companies

	1st Jan change	Capi.
CHURCHILL CAPITAL CORP VII	+2.67%	987M
PERELLA WEINBERG PARTNERS	+46.93%	961M
ARES ACQUISITION CORPORATION II	+2.39%	668M
DA ZHONG TRADING GROUP HOLDING COMPANY	-.--%	600M
E7 GROUP	-2.15%	582M
ADMIRAL ACQUISITION LIMITED	+10.28%	536M
CAPITOL INVESTMENT CORP. VII	-.--%	500M
AEA-BRIDGES IMPACT CORP.	+3.47%	470M
DONG FANG HUI LE INC.	-.--%	450M

Shell Companies